Andrea L. Webber - Researcher Profile

Publications

2 shown

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

2018 The Lancet Oncology 2448 citations

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu , Robin Mogg , Mark Ayers +21 more

Mining immunotherapy clinical trials Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies...

2018 Science 2202 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,650
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-2463-0878

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.